Status: Recruiting
Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma
The goal of this single-arm study is to explore the efficacy and safety of Adebrelimab in combination with Apatinib and Tegafur for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma that has failed first-line standard treatment with PD-1 inhibitors in combination with chemotherapy.
Participants needed: 32
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityUpdated: Jun 4, 2026Locations: 1
Eligibility criteria
18-75 years old, both sexes. [+9]
Have been diagnosed with other malignancies within 5 years, excluding: curable c... [+21]